Eupraxia Net Working Capital from 2010 to 2026
| EPRX Stock | 8.28 0.07 0.84% |
Net Working Capital | First Reported 2010-12-31 | Previous Quarter 36 M | Current Value 37.8 M | Quarterly Volatility 21.6 M |
Check Eupraxia Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eupraxia Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 161.5 K, Interest Expense of 1 M or Selling General Administrative of 19 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.79. Eupraxia financial statements analysis is a perfect complement when working with Eupraxia Pharmaceuticals Valuation or Volatility modules.
Eupraxia | Net Working Capital | Build AI portfolio with Eupraxia Stock |
The evolution of Net Working Capital for Eupraxia Pharmaceuticals Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Eupraxia Pharmaceuticals compares to historical norms and industry peers.
Latest Eupraxia Pharmaceuticals' Net Working Capital Growth Pattern
Below is the plot of the Net Working Capital of Eupraxia Pharmaceuticals Common over the last few years. It is Eupraxia Pharmaceuticals' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eupraxia Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Working Capital | 10 Years Trend |
|
Net Working Capital |
| Timeline |
Eupraxia Net Working Capital Regression Statistics
| Arithmetic Mean | (2,426,785) | |
| Coefficient Of Variation | (888.93) | |
| Mean Deviation | 18,581,683 | |
| Median | (16,785,358) | |
| Standard Deviation | 21,572,527 | |
| Sample Variance | 465.4T | |
| Range | 54.6M | |
| R-Value | 0.82 | |
| Mean Square Error | 163.3T | |
| R-Squared | 0.67 | |
| Significance | 0.000058 | |
| Slope | 3,499,422 | |
| Total Sum of Squares | 7446T |
Eupraxia Net Working Capital History
About Eupraxia Pharmaceuticals Financial Statements
Eupraxia Pharmaceuticals investors use historical fundamental indicators, such as Eupraxia Pharmaceuticals' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eupraxia Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 36 M | 37.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eupraxia Stock Analysis
When running Eupraxia Pharmaceuticals' price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.